Pilot Study: Access to Fitness Facility and Exercise Levels in Olanzapine-Treated Patients

Canadian Journal of Psychiatry

Volumn 48, Issue 9, 2003, Pages 628-632

  Archie, Suzanne ^a,b,c   Wilson, Jane Hamilton ^b   Osborne, Shelley ^b   Hobbs, Heather ^b   McNiven, Jean ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

^c MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Exercise; Olanzapine; Schizophrenia; Weight gain

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE;

ADULT; ARTICLE; BODY WEIGHT DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXERCISE; FEMALE; HEALTH CARE ACCESS; HEALTH CARE UTILIZATION; HEALTH CENTER; HUMAN; MALE; MOTIVATION; PATIENT COMPLIANCE; PILOT STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 0242427525     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370304800910     Document Type: Article

References (14)

1. Colvin RH, Olson S B. A descriptive analysis of men and women who have lost significant weight and are highly successful at maintaining the loss. Addict Behav 1983;8:287-95.
2. Hoiberg A, Berard S, Watten RH, Caine C. Correlates of weight loss in treatment and at follow-up. Int J Obes 1984;8:457-65.
3. Marston AR, Criss J. Maintenance of successful weight loss: incidence and prediction. Int J Obes 1984;8:435-9.
4. Greenberg I, Chan S, Blackburn GL. Nonpharmacologic and pharmacologic management of weight gain. J Clin Psychiatry 1999;60(Suppl 21):S31-S36.
5. Stanniland C, Taylor D. Tolerability of atypical antipsychotics. Drug Safe 2000;22:195-214.
6. Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997;154:1248-54.
7. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, and others. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-18.
8. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, and others. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-63.
9. Taylor DM, McAskill R. Atypical antipsychotics and weight gain a systematic review. Acta Psychiatr Scand 2000;101:416-32.
10. Kawachi I. Physical and psychological consequences of weight gain. J Clin Psychiatry 1999;60(Suppl 21):S5-S9.
11. Bernstein JG. Psychotropic drug induced weight gain: mechanisms and management. Clin Neuropharmacol 1988;11(Suppl 1):S194-S206.
12. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999;60:767-70.
13. Hockey RV. Physical fitness: the pathway to healthful living. 7th ed. St. Louis: Mosby; 1993.
14. Prochaska JO, Velicer WF, Rossi JS, Goldstein MG, Marcus BH, Rakowski W, and others. Stages of change and decisional balance for 12 problem behaviors. Health Psychol 1994;13(1):39-46.